LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Objective: A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). Methods: LY3298176 is a fatty acid modified peptide wit...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tamer Coskun, Kyle W. Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B. Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles T. Benson, Ruth E. Gimeno, David A. D'Alessio, Axel Haupt
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2018-12-01
coleção:	Molecular Metabolism
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2212877818309001
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!